Accelerating Medicines Partnership® Program – Alzheimer's Disease 2.0
Enhancing target discovery for Alzheimer’s disease
The Accelerating Medicines Partnership® (AMP®) Program Alzheimer’s disease (AMP AD 2.0) is a precompetitive public-private partnership that will enable precision medicine research for Alzheimer’s disease through deep and longitudinal molecular analyses across diverse populations to provide insights that will accelerate the development of therapies for Alzheimer’s disease.
This multisector partnership, managed by the Foundation for the NIH, will focus on providing a data-driven approach for identification and validation of biomarkers that will lead to increased clinical trial success.
AMP AD 2.0 builds on the success of AMP AD 1.0 and joins a portfolio of AMP programs that use cutting-edge scientific approaches to bring new medicines and support to patients by enhancing validation of novel, clinically relevant therapeutic targets and biomarkers.
About Alzheimer’s Disease
Alzheimer's disease is projected to affect approximately 14 million people by the year 2060. Alzheimer’s is a progressive brain disorder that is the most common cause of dementia in older adults. Dementia is the loss of thinking, remembering and reasoning abilities (neuro cognitive functions) to the extent that it interferes with a person’s daily life and activities. It is not a normal part of aging and has many potential causes. Alzheimer’s disease is characterized by changes in the brain called amyloid plaques and tau tangles as well as a loss of connections between nerve cells (neurons) in the brain. Neurons transmit messages between different parts of the brain, and from the brain to muscles and organs in the body. AMP AD works to further unravel the complex molecular changes involved in Alzheimer’s disease to speed up identification of novel drug targets. For more information on Alzheimer’s disease and related dementias click here.
Need for New Therapies
Despite substantial investment in Alzheimer's disease research, the treatment options available today only temporarily improve symptoms without stopping the underlying decline and death of brain cells. Given the extremely high failure rate for investigative Alzheimer’s treatments – nearly 100 percent – this field needs innovations like AMP AD to enable an understanding of the complex biology and heterogeneity of the disease process.
Read more about AMP AD 2.0 on the National Institute on Aging’s website.
AMP AD Knowledge Portal
Click here to discover and download Alzheimer's disease data, analyses, and tools from AMP AD.
AMP AD Agora Platform
Agora is an open-source platform, created to provide curated AMP AD verified systems biology analyses showing which genes are associated with Alzheimer's disease. Click here to learn more.
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institute on Aging (NIA)
- U.S. Food and Drug Administration (FDA)
*Provided financial support for this project.
- Identify and validate new targets and biomarkers associated with different molecular subtypes of the disease to enable drug developers to select the right populations of patients for targeted treatments in clinical trials.
- Enable mapping of Alzheimer’s disease progression on a cellular and molecular level and increase the availability of longitudinal data, giving researchers a more detailed and dynamic understanding of the disease.
- Increase access to de-identified data from racially and ethnically diverse cohorts by prioritizing the addition of information to its centralized knowledge portal from populations most at risk, including Black and Latinx.
- Enhance data-sharing capabilities by making individual subject-level data, analytical outputs, and target nominations available to researchers worldwide for use in basic research and therapy development.
Over 200 publications based on AMP AD datasets, to explore publications click here.
Molecular estimation of neurodegeneration pseudotime in older brains – Nature Communications
Sex and APOE ε4 genotype modify the Alzheimer’s disease serum metabolome – Nature Communications
Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer's disease – Nature Communications
Deciphering cellular transcriptional alterations in Alzheimer's disease brains – Molecular Neurodegeneration
Multiscale causal networks identify VGF as a key regulator of Alzheimer’s disease – Nature Communications
FNIH Press Release (March 2021): Foundation for the NIH announces Alzheimer’s disease research initiative to accelerate progress on treatments
NIA Press Release (March 2021): NIH reinvests in transformative public-private partnership to advance precision medicine research for Alzheimer’s disease
For more information about supporting or becoming a partner in this project, please contact Heidi Blythe, Director, Strategic Alliances and Advancement, email@example.com.
ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the U.S. Department of Health and Human Services.